Headquarters: Ness Ziona, Israel
Investor Relations: Eric Ribner / eric@lifesciadvisors.com
Description
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions.
Industry
Life Sciences
Year Founded
Ownership
Public
Exchange / Symbol
NASDAQ: ENLV
Public Since
Chief Executive Officer
Chairman of the Board
Chief Financial Officer
Insider Ownership
Key Investors
Employee Count
Auditors
Investment Bankers
Law Firms
In the CEOs Own Words
Corporate Mission
Proudest Accomplishment
Next Milestone
Geographic Markets Served
Growth Drivers
Growth Headwinds
Indicia of Customer Satisfaction
Scalability
Workforce
Focus of Recruitment
Research and Development
Patent Count
Economic Sensitivity
Unique Metrics
Greatest Concern
Company Reports and Communications
SEC Filings
" target="_blank">